| human | Q5 |
| P10058 | IRIS UNIBO author ID | 36806 |
| P496 | ORCID iD | 0000-0003-1486-2624 |
| P1153 | Scopus author ID | 7004207003 |
| P734 | family name | Fanti | Q37322215 |
| Fanti | Q37322215 | ||
| Fanti | Q37322215 | ||
| P735 | given name | Stefano | Q650375 |
| Stefano | Q650375 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q39699773 | (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. |
| Q48139886 | (11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel. |
| Q53132955 | (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy. |
| Q37173356 | (11)C-meta-hydroxyephedrine PET/CT imaging allows in vivo study of adaptive thermogenesis and white-to-brown fat conversion. |
| Q52984458 | (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial. |
| Q40707077 | (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging. |
| Q53505313 | (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? |
| Q52996168 | (68)Ga-PSMA-PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse After Radical Prostatectomy for Prostate Cancer. |
| Q38970106 | 11C- or 18F-Choline PET/CT for Imaging Evaluation of Biochemical Recurrence of Prostate Cancer |
| Q46719854 | 11C-choline PET/CT and bladder cancer: lymph node metastasis assessment with pathological specimens as reference standard. |
| Q39293042 | 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. |
| Q46434290 | 11C-choline PET/CT for restaging of bladder cancer. |
| Q46084522 | 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer. |
| Q38229217 | 11C-mHED for PET / CT: principles of synthesis, methodology and first clinical applications |
| Q38226841 | 11C-meta-hydroxyephedrine: a promising PET radiopharmaceutical for imaging the sympathetic nervous system. |
| Q53091484 | 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. |
| Q40404841 | 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease |
| Q53088031 | 18F-FDG PET/CT impact on testicular tumours clinical management. |
| Q47114573 | 18F-FDG Pet-Guided External Beam Radiotherapy in Iodine-Refractory Differentiated Thyroid Cancer: A Pilot Study. |
| Q34479713 | 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT. |
| Q53065988 | 68Ga DOTANOC PET/CT detects primary malignant insulinoma. |
| Q38230179 | 68Ga-DOTA-peptides in the diagnosis of NET. |
| Q46225464 | 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. |
| Q38832649 | A Comparison of Different Staging Systems for Multiple Myeloma: Can the MRI Pattern Play a Prognostic Role? |
| Q56959711 | A Rare Case of Epididymal Metastasis After Radical Prostatectomy Detected by 68Ga-PSMA PET/CT |
| Q118142218 | A [68Ga]Ga-DOTANOC PET/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours |
| Q46812310 | Accurate modeling of a DOI capable small animal PET scanner using GATE. |
| Q34451031 | Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. |
| Q53120424 | Cardiac FDG PET/CT is useful to assess the culprit lesion in nonST-segment elevation myocardial infarction (NSTEMI). |
| Q40876672 | Cardiac resynchronization therapy and cardiac sympathetic function |
| Q49886719 | Cholescintigraphic patterns in a IBS patient with postprandial diarrhea. |
| Q51161624 | Collection of hematopoietic stem cells after previous radioimmunotherapy is feasible and does not impair engraftment after autologous stem cell transplantation in follicular lymphoma. |
| Q44571451 | Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. |
| Q30444028 | Combined computed tomography and fluorodeoxyglucose positron emission tomography in the diagnosis of prosthetic valve endocarditis: a case series. |
| Q47207206 | Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. |
| Q56966488 | Complete pathological response after chemo-radiation in anaplastic thyroid cancer: A report of two cases |
| Q64030381 | Consensus on molecular imaging and theranostics in prostate cancer |
| Q91342921 | Contribution of PET imaging to mortality risk stratification in candidates to lead extraction for pacemaker or defibrillator infection: a prospective single center study |
| Q48545330 | Correction to: 18F-NaF PET/CT: EANM procedure guidelines for bone imaging. |
| Q57470925 | Correction to: Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine |
| Q47241139 | Current status of theranostics in prostate cancer. |
| Q56343006 | Delivering PET imaging results to cancer patients: steps for handling ethical issues |
| Q46282200 | Development and validation of RAYDOSE: a Geant4-based application for molecular radiotherapy. |
| Q40188618 | Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions |
| Q46476500 | Diagnostic accuracy of (11)C-choline PET/CT in preoperative lymph node staging of bladder cancer: a systematic comparison with contrast-enhanced CT and histologic findings. |
| Q53063325 | Diagnostic accuracy of FDG PET/CT in mediastinal lymph nodes from lung cancer. |
| Q39369144 | Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view. |
| Q52984337 | Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT? |
| Q90258312 | EANM Focus 1: one small step for two men, one giant leap for a specialty |
| Q57679967 | ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging |
| Q38927370 | Early and delayed evaluation of solid tumours with 64Cu-ATSM PET/CT: a pilot study on semiquantitative and computer-aided fractal geometry analysis. |
| Q56973144 | Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy? |
| Q48217029 | Effects of cardiac resynchronization therapy on right ventricular function during rest and exercise, as assessed by radionuclide angiography, and on NT-proBNP levels. |
| Q53527867 | Endotracheal metastasis from colorectal cancer. |
| Q46633708 | Engineered porphyrin loaded core-shell nanoparticles for selective sonodynamic anticancer treatment |
| Q48152224 | Erratum to: Guideline for PET/CT imaging of neuroendocrine neoplasms with (68)Ga-DOTA-conjugated somatostatin receptor targeting peptides and (18)F-DOPA. |
| Q38970109 | Evaluation of Prostate Cancer with 11C-Choline PET/CT for Treatment Planning, Response Assessment, and Prognosis. |
| Q38970117 | Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs |
| Q57823479 | F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature |
| Q33275556 | FDG PET/CT for bone and soft-tissue biopsy |
| Q56974117 | FDG PET/CT in autoimmune pancreatitis |
| Q50034729 | FDG-PET/CT Guided Biopsy in Angiosarcoma of Bone: Diagnosis, Staging and Beyond. |
| Q39114508 | First case of 18F-FACBC PET/CT-guided salvage radiotherapy for local relapse after radical prostatectomy with negative 11C-Choline PET/CT and multiparametric MRI: New imaging techniques may improve patient selection. |
| Q39295622 | First case of 18F-FACBC PET/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer and negative 11C-choline PET/CT: new imaging techniques may expand pioneering approaches. |
| Q91864540 | Fluoride PET/CT in Metastatic Benign Pulmonary Calcification |
| Q34507817 | GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers. |
| Q56379286 | Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy |
| Q57802680 | Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy |
| Q48089118 | Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. |
| Q51822698 | Heterogeneous response of cardiac sympathetic function to cardiac resynchronization therapy in heart failure documented by 11[C]-hydroxy-ephedrine and PET/CT. |
| Q91862099 | Highlights from 2017: impactful topics published in the Annals of Nuclear Medicine |
| Q51237810 | Highlights of the 26th EANM 2013 congress in Lyon: new horizons and further. |
| Q56336017 | Highlights of the 30th Annual Congress of the EANM, Vienna 2017: "Yes we can - make nuclear medicine great again" |
| Q38609472 | Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe). |
| Q38321182 | Imaging biomarkers in prostate cancer: role of PET/CT and MRI. |
| Q38655167 | Imaging for Prostate Cancer Recurrence. |
| Q39166080 | Imaging of Prostate Cancer Using 11C-Choline PET/Computed Tomography |
| Q56359100 | Imaging of Prostate Cancer Using C-Choline PET/Computed Tomography |
| Q38204578 | Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging. |
| Q51058133 | Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial. |
| Q53059202 | Improving PET spatial resolution and detectability for prostate cancer imaging. |
| Q30831523 | Incidentally detected increased FDG uptake in bowel and its correlation with hystopathological data: our experience in a case series study. |
| Q48360689 | Interpretation criteria for FDG PET/CT in multiple myeloma (IMPeTUs): final results. IMPeTUs (Italian myeloma criteria for PET USe). |
| Q57817247 | Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy? |
| Q48205881 | Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis |
| Q31108842 | METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. |
| Q90763442 | Male Breast Cancer Detected by 68Ga-PSMA-11 PET/CT in a Patient With Prostate Cancer With Pelvic Lymph Node Metastasis |
| Q38706310 | Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. |
| Q35879087 | Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. |
| Q39013373 | Molecular Imaging and Precision Medicine in Prostate Cancer. |
| Q36673633 | Molecular imaging of neuroblastoma progression in TH-MYCN transgenic mice. |
| Q42379563 | Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (18F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer |
| Q39437137 | New aspects of molecular imaging in prostate cancer. |
| Q38268168 | Nuclear medicine in urological cancers: what is new? |
| Q86501891 | Of standard of reference and accuracy: the problem of truth in imaging |
| Q39003086 | PET Tracers Beyond FDG in Prostate Cancer. |
| Q52986488 | PET in natural killer/T-cell lymphoma: the debate continues. |
| Q41666443 | PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma. |
| Q53772593 | PET/CT imaging for evaluating response to therapy in castration-resistant prostate cancer. |
| Q31003607 | PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data |
| Q38589076 | PET/Computed Tomography in the Individualization of Treatment of Prostate Cancer. |
| Q39258574 | Performance of FDG PET/ceCT in the evaluation of patients with lung cancer |
| Q37249774 | Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients |
| Q45961614 | Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. |
| Q41192078 | Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer |
| Q56352591 | Preoperative Staging With C-Choline PET/CT Is Adequately Accurate in Patients With Very High-Risk Prostate Cancer |
| Q46221537 | Pretherapeutic dosimetry in patients affected by metastatic thyroid cancer using 124I PET/CT sequential scans for 131I treatment planning. |
| Q40454562 | Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With 64Cu-ATSM PET/CT. |
| Q48511644 | Prognostic Impact of Pretreatment Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography SUVmax in Patients With Locally Advanced Cervical Cancer. |
| Q40503265 | Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas. |
| Q57813338 | Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review |
| Q56349857 | Prognostic value of posttreatment F-FDG PET/CT and predictors of metabolic response to therapy in patients with locally advanced cervical cancer treated with concomitant chemoradiation therapy: an analysis of intensity- and volume-based PET parameter |
| Q87345538 | Prognostic value of ¹⁸F-DOPA PET/CT at the time of recurrence in patients affected by neuroblastoma |
| Q56969116 | Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy |
| Q53000997 | Prospective international cohort study demonstrates inability of interim PET to predict treatment failure in diffuse large B-cell lymphoma. |
| Q53038280 | Prostate cancer: Identifying sites of recurrence with choline-PET-CT imaging. |
| Q56927425 | Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: Real-world experience |
| Q58577276 | Radioguided surgery with β radiation: a novel application with Ga |
| Q38911001 | Rapidly changing landscape of PET/CT imaging in prostate cancer. |
| Q55686724 | Rapidly growing pulmonary ground-glass nodule caused by metastatic melanoma lacking uptake on 18F-FDG PET-CT. |
| Q53136945 | Rationale for Modernising Imaging in Advanced Prostate Cancer. |
| Q50957944 | Relation between thoracic aortic inflammation and features of plaque vulnerability in the coronary tree in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention. An FDG-positron emission tomogra |
| Q46396519 | Reply to "¹⁸F-2-fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography in predicting pathologic complete response after neoadjuvant chemotherapy: the early metabolic response is the answer". |
| Q51408525 | Reply to Egesta Lopci, Arturo Chiti, and Massimo Lazzeri's Letter to the Editor re: Laura Evangelista, Alberto Briganti, Stefano Fanti, et al. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising |
| Q56967715 | Reply to the letter to the editor 'management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015' by Gillessen et al |
| Q86190306 | Reply: Critical views on the prognostic potential and interpretation of bone marrow 18F-FDG PET in diffuse large B-cell lymphoma |
| Q45979396 | Restaging clear cell renal carcinoma with 18F-FDG PET/CT. |
| Q56383753 | Risk-related F-FDG PET/CT and new diagnostic strategies in patients with solitary pulmonary nodule: the ITALIAN multicenter trial |
| Q56973389 | Role of ¹⁸F-FDG PET/CT in the diagnosis of infective endocarditis in patients with an implanted cardiac device: a prospective study |
| Q90592519 | Single Subcutaneous Prostate Cancer Metastasis Detected by 68Ga-PSMA PET/CT During Early Biochemical Relapse: A Case Report |
| Q57105800 | State-of-the-art imaging techniques in the management of preoperative staging and re-staging of prostate cancer |
| Q40155361 | Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. |
| Q38762963 | Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. |
| Q48643223 | The Effect of Susceptibility Artifacts Related to Metallic Implants on Adjacent-Lesion Assessment in Simultaneous TOF PET/MR. |
| Q39023651 | The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis. |
| Q38870163 | The Possible Role of PET Imaging Toward Individualized Management of Bone and Soft Tissue Malignancies. |
| Q50860354 | The Wandering Mesenteric Lymph Node: Delayed 68Ga-DOTANOC PET/CT Imaging to Overcome a Potential Pitfall. |
| Q44600799 | The additional diagnostic value of contemporary evaluation of FDG PET/CT scan and contrast enhanced CT imaging both acquired by a last generation PET/CT system in oncologic patients. |
| Q47672298 | The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. |
| Q46208557 | The detection of disease relapse after radical treatment for prostate cancer: is anti-3-18F-FACBC PET/CT a promising option? |
| Q50881880 | The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL. |
| Q47794903 | The role of 18F-FDG PET/CT in the detection of osteosarcoma recurrence |
| Q37560522 | The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas |
| Q53049216 | The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients. |
| Q38230239 | The use of gallium-68 labeled somatostatin receptors in PET/CT imaging |
| Q53134754 | The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients. |
| Q39328036 | Therapy assessment in prostate cancer using choline and PSMA PET/CT. |
| Q38667997 | Unusual Thyroid Carcinoma Metastases: a Case Series and Literature Review |
| Q44018946 | Use of 65Zn as a tracer for the assessment of purification in the 68Ga-DOTANOC synthesis. |
| Q44257594 | Usefulness of 64Cu-ATSM in head and neck cancer: a preliminary prospective study. |
| Q45758695 | ¹⁸F-FDG PET/CT diagnosis of unexpected extracardiac septic embolisms in patients with suspected cardiac endocarditis. |
Search more.